Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Overview of attention for article published in New England Journal of Medicine, January 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 59 news outlets
blogs: 2 blogs
policy: 8 policy sources
twitter: 155 X users
patent: 38 patents
facebook: 15 Facebook pages

wikipedia: 7 Wikipedia pages
f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 11 clinical guideline sources
podcasts: 6 podcasts

Readers on

mendeley: 1611 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 93 news stories from 59 outlets.

Neuroendocrine Tumor Patients Gain a Second Lutetium Dotatate Option as FDA Approves Curium's Bexlutry Radioligand Injection

inkl, 17 Sep 2026

Adults with the most common group of neuroendocrine tumors now have a second FDA-approved version of lutetium Lu 177 dotatate…

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine

Oncodaily, 15 Sep 2026

The U.S. Food and Drug Administration (FDA) has approved Bexlutry (lutetium Lu 177 dotatate) for the treatment of adults with…

ルタテラ：神経内分泌腫瘍をより良く治療する機会の逸失

Nipponese.news, 19 Jan 2026

神経内分泌腫瘍は稀な腫瘍のカテゴリーに含まれており、全体の年間発生率は住民 10 万人あたり約 5 人です。これらは、主に影響を受ける臓器の位置、ペプチドホルモンまたは血管作動性アミンを産生する能力、生物学的特徴、およびその結果として生じる臨床経過および予後…

News story from Le Quotidien du Medicin on Thursday 18 December 2025

Le Quotidien du Medicin, 18 Dec 2025

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 89 additional news stories.